search

About CanImGuide

  1. Home
  2. chevron_right
  3. About CanImGuide

A company with …

a novel, simple but sophisticated and highly innovative, peptide approach to immuno-oncology. P28R as a drug concept is extraordinary. It is a First-In-Class, being the first and only immunomodulatory peptide in the IO field.

CanImGuide has discovered, and thoroughly demonstrated, that a previously unknown immunosuppressive peptide named P3028 is formed in malignant tumors through the breakdown of albumin. This intra-tumoral albumin peptide binds to the LFA-1 receptor (an integrin with a key role in immune cell functioning) and is thereby blocking an important component in the natural immune defense that normally contributes to kill cancer cells.

Our Solution

The nonclinical studies performed by CanImGuide have clearly demonstrated that this peptide drug treatment is efficacious in essentially all torms of spontaneous tumors in dogs (which have a similar immune system and develop cancer similar to humans) and that it is very safe. Based on the mode of action and the safety profile, as well as an initial checkpoint inhibitor combo study, it is anticipated that this novel drug can be used both as monotherapy and in combination with other anti-cancer treatments. Swedish MPA reviewed the submission file of CanImGuide earlier this year and have given their approval to start testing the drug (P28R) in patients with head-and-neck cancer. Clinical trial will be initiated d2018.

The story in brief

2006
2008
2011
2013
2015
2018
2019
2006

Our Birth

CanImGuide Therapeutics AB (CanImGuide) was founded in 2006 in order to further develop new treatments for primarily cancer, based on research carried out by a team led by Professor Leif Håkansson at the University of Linköping, Sweden.

Suppressor of the immune system

Their research clearly indicated the possibility to predict the therapeutic outcome of immunotherapy based on either intra-tumoural or systemic immune status and it was also shown that the systemic immune status could be used to develop prognostic tests of significant value for cancer patients.

2008

Peptide 3028 was discovered

Based on these observations the potential role of suppressive peptide sequences in cancer immunosuppression was further explored and the potent, suppressive peptide 3028 was discovered. Peptide 3028 has a dual mechanism of action, binding to two receptors of fundamental importance for the function of immune cells with the potential to suppress several steps in initiation and up-regulation of an immune response.

By investigating the underlying immune-regulatory mechanisms, Leif Håkansson and his team was also able to detect several previously unknown therapeutic targets in cancer, as well as in inflammatory diseases.

2011

A lead drug candidate

Antibodies to the suppressive peptide 3028 were developed and these antibodies were, in a human ex vivo model, shown to efficiently overcome this type of immunosuppression. A low molecular weight substance directed against this structure comprises a lead drug candidate for treatment of immunosuppression in cancer patients. This therapeutic strategy will enhance immune mediated anti-cancer reactivity and enhance the efficacy of immunostimulatory treatment using interferons, interleukins and vaccination.

2013

The discovery of a new class of immuno-regulatory substances

In 2013 CanimGuide developed the peptide P28R which targets the P3028-structure and inactivates it.

 

2015

Fundamental therapeutic breakthrough

In vivo studies performed in 2015 demonstrating that P28R executes its anti-cancer effects also following subcutaneous administration (into healthy tissues), achieving systemic treatment effects. This was a fundamental therapeutic breakthrough in the development of P28R.

Toxicological studies conducted without any significant side effects.

2018

First in-human clinical trials

Based on the results achieved to date, the company is next planning to initiate its first-in-human clinical trial in patients. This will be a limited size study in patients with head-and-neck cancer. The clinical trial protocol is under review by the Swedish MPA and the Ethical Committee and will be initiated during 2018.
2019

Preparing Phase I/II studies

Canimguide will carry out several Non-Clinical development activities which aim to prepare for the clinical development programs and a Phase I/II study. These activities includes a Regulatory Toxicological study, experimental invivo tumour studies, three clinical trials in dog, and a clinical Phase 0 First-In-Human study. All these activities will provide indispensable guidance for the more advanced Phase I/II studies planned to start in 2020.

Business model

CanImGuide plans to take P28R to proof of concept in cancer patients and will then partner their immune-oncology program with a Pharma partner with a presence in this particular area. Thus, the preparations of the next clinical trial will now be initiated in parallel with executing and completing the First-in-Man trial. Initial discussions with potential Pharma partners and tentative collaboration projects, such as combo studies will be part of the awareness.

Menu